Status:

COMPLETED

Double Blind Study to Evaluate the Efficacy of Collagenase Histolyticum in the Treatment of Lipoma

Lead Sponsor:

Gerut, Zachary, M.D.

Collaborating Sponsors:

Advance Biofactures Corporation

Conditions:

Lipoma

Eligibility:

All Genders

18-75 years

Phase:

PHASE2

Brief Summary

The purpose of this study is to determine whether collagenase is effective in reducing the surface area of a subcutaneous benign lipoma.

Detailed Description

This study will evaluate the safety and efficacy of a Food and Drug Administration (FDA) approved drug (XIAFLEX) in the treatment of lipoma (fatty tumors). The fat in the lipoma is like normal fat exc...

Eligibility Criteria

Inclusion

  • 18-75 years of age, of either sex or any race
  • Clinical history of at least 2 lipomas for at least one year
  • Lipomas diagnosed as benign
  • Two lipomas on distinctly separate parts of the body, or on the torso if 30 cm apart, with easily definable edges
  • Each lipoma is a single mass with easily definable edges
  • Lipomas are 5 to 24 cm squared
  • Women of childbearing potential must use an acceptable method of birth control

Exclusion

  • Lipomas on the head, neck, hand or foot, or female breast
  • Women who are nursing or pregnant
  • Multi-lobular lipomas
  • Subjects who have received an investigational drug within 30 days before receiving the first dose of study drug in this study
  • Subjects with a known allergy to collagenase or any of the inactive ingredients in XIAFLEX
  • Subjects with uncontrolled diabetes, hypertension, or thyroid disease, or any medical condition that would make the subject unsuitable for enrollment
  • Subjects having prior treatment or trauma of the lipoma that could interfere with study assessments
  • Subjects with a history of connective tissue diseases, rheumatological diseases
  • Subjects taking anticoagulants or planning to receive anticoagulants (except for lo dose aspirin and over-the-counter nonsteroidal anti-inflammatory drugs) within 7 days of injection of study drug

Key Trial Info

Start Date :

August 1 2014

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 1 2016

Estimated Enrollment :

19 Patients enrolled

Trial Details

Trial ID

NCT02249052

Start Date

August 1 2014

End Date

June 1 2016

Last Update

February 23 2017

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Aesthetic Center

Hewlett, New York, United States, 11557

2

Vanderbilt University

Nashville, Tennessee, United States, 37232

Double Blind Study to Evaluate the Efficacy of Collagenase Histolyticum in the Treatment of Lipoma | DecenTrialz